CoChat

The DOI matches its Crossref record.

Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial

Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., Emrich, H. · 2002 · Pharmacopsychiatry

Abstract

Anecdotal reports in Tourette's syndrome (TS) have suggested that marijuana (cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, reduce tics and associated behavioral disorders. We performed a randomized double-blind placebo-controlled crossover single-dose trial of Delta(9)-THC (5.0, 7.5 or 10.0 mg) in 12 adult TS patients. Tic severity was assessed using a self-rating scale (Tourette's syndrome Symptom List, TSSL) and examiner ratings (Shapiro Tourette's syndrome Severity Scale, Yale Global Tic Severity Scale, Tourette's syndrome Global Scale). Using the TSSL, patients also rated the severity of associated behavioral disorders. Clinical changes were correlated to maximum plasma levels of THC and its metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). Using the TSSL, there was a significant improvement of tics (p=0.015) and obsessive-compulsive behavior (OCB) (p = 0.041) after treatment with Delta(9)-THC compared to placebo. Examiner ratings demonstrated a significant difference for the subscore "complex motor tics" (p = 0.015) and a trend towards a significant improvement for the subscores "motor tics" (p = 0.065), "simple motor tics" (p = 0.093), and "vocal tics" (p = 0.093). No serious adverse reactions occurred. Five patients experienced mild, transient side effects. There was a significant correlation between tic improvement and maximum 11-OH-THC plasma concentration. Results obtained from this pilot study suggest that a single-dose treatment with Delta(9)-THC is effective and safe in treating tics and OCB in TS. It can be speculated that clinical effects may be caused by 11-OH-THC. A more long-term study is required to confirm these results.

Overview

Integrity signals

Registry

Crossref · 10.1055/s-2002-25028

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

See all 256

Metadata

Authors
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • Heinrich Heine University Düsseldorf (DE)
Venue
Pharmacopsychiatry
Published
2002-04-12
Volume
35
Issue
02
Pages
57-61
ISSN
  • 0176-3679 (ISSN-L)
  • 1439-0795
OpenAlex
W2041869734
Cited by
256
References
0
Citations by year
2026: 6 · 2025: 12 · 2024: 10 · 2023: 23 · 2022: 29 · 2021: 16 · 2020: 18 · 2019: 12 · 2018: 13 · 2017: 12 · 2016: 7 · 2015: 11 · 2014: 9 · 2013: 5 · 2012: 8
FWCI
12.84
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacopsychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
Tourette syndrome, delta-9-tetrahydrocannabinol, cannabis, tics, obsessive-compulsive behavior, 11-hydroxy-THC, THC metabolites, single-dose therapy, vocal tics, treatment efficacy and safety
MeSH terms
Adolescent, Adult, Aged, Double-Blind Method, Female, Tourette Syndrome, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Dronabinol, Treatment Outcome, Cross-Over Studies, Tics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. https://app.cochat.ai/papers/10.1055/s-2002-25028
The paper
Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. (2002). Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry. https://doi.org/10.1055/s-2002-25028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.